1
Clinical Trials associated with Autologous CD30 CAR-T(Shanxi Bethune Hospital) / RecruitingNot ApplicableIIT Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor Gene Modified T Cells Targeting CD30 in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
The is a prospective, open-label, dose-climbing clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
100 Clinical Results associated with Autologous CD30 CAR-T(Shanxi Bethune Hospital)
100 Translational Medicine associated with Autologous CD30 CAR-T(Shanxi Bethune Hospital)
100 Patents (Medical) associated with Autologous CD30 CAR-T(Shanxi Bethune Hospital)
100 Deals associated with Autologous CD30 CAR-T(Shanxi Bethune Hospital)